UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 8, 2017

Qrons Inc.
(Exact name of registrant as specified in its charter)

Wyoming
(State or other jurisdiction of incorporation)

000-55800
81-3623646
 (Commission File Number)  (IRS Employer Identification No.)
 
777 Brickell Avenue, Suite 500, Miami, Florida 33131
 (Address of principal executive offices) (Zip Code)
 
(786)-620-2140
(Registrant's telephone number, including area code)

----------------------------------------------------------------------
 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the  Securities Exchange Act of 1934 (§240.12b-2 of this chapter).       
 
                                                                                                                                                                                        Emerging growth company [X]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]



1
Section Corporate Governance and Management
Item 5.03 Amendments to Articles of Incorporation or Bylaws

On July 6, 2017, the board of directors and shareholders of Qrons Inc. (the "Company") approved an amendment to the Company's Articles of Incorporation changing the name of the Company from "BioLabMart Inc." to "Qrons Inc.", as described in the Company's Schedule 14C Information Statement filed with the SEC on July 18, 2017.

The Secretary of State of the State of Wyoming approved the Company's Amendment to Articles of Amendment reflecting such name change, effective August 8, 2017.

FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC market became effective at the open of business August 10, 2017.

Section 8 – Other Events
Item 8.01 Other Events

On August 11, 2017, the Company issued a press release announcing the name change.

Section 9 – Financial Statements and Exhibits
Item 9.01.  Financial Statements and Exhibits

(d)   Exhibits.

Exhibit No .   Description

3.4                   Amendment to Articles of Incorporation

99.1                 Press Release, dated August 11, 2017


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

  Qrons Inc.  
       
Date: August 11, 2017
By:
/s/ Jonah Meer  
    Name: Jonah Meer  
    Title: Chief Executive Officer  
       
 
2


AMENDMENT TO ARTICLES OF INCORPORATION
OF
BIOLABMART INC.

BioLabMart Inc., a corporation organized and existing under the laws of the State of Wyoming, hereby certifies as follows:
1.   The name of the corporation is BioLabMart Inc.  The date of filing of its original Articles of Incorporation with the Secretary of State was August 22, 2016.
2.   This Amendment amends Article I of the Articles of Incorporation of this corporation by replacing the name "BioLabMart Inc." with the name "Qrons Inc.".
3.   This Amendment was adopted on July 6, 2017.
4.   Shares were issued and the board of directors have adopted this Amendment with shareholder approval, in compliance with W.S. 17-16-1003.
5.   The effective date of this Amendment is to be August 8, 2017.

Signed on this 1st day of August, 2017
/s/ Jonah Meer
Jonah Meer
Chief Executive Officer





FOR IMMEDIATE RELEASE

INVESTOR AND MEDIA CONTACT
Qrons Inc.
Mr. Jonah Meer
E: jmeer@qrons.com
P: 786-620-2140


BioLabMart Inc. Announces Company Name Change
to Qrons Inc.
 
MIAMI, Florida, August 11, 2017/PR.COM/ – BioLabMart Inc, (OTC PINK/Trading Symbol: BLMB) ("the Company"), a startup preclinical stage biotechnology company, is pleased to announce that the company has changed its name to Qrons Inc., and has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 74737F101.
 
"Qrons Inc. more accurately reflects the nature of our research of dealing with the treatment of neuro-degenerative diseases and neuronal injuries," commented Jonah Meer and Ido Merfeld, co-founders and Chief Executive Officer and President, respectively, of the Company.

The Company's common stock  traded under stock symbol "BLBM" on OTC PINK until market close on August 9, 2017. Trading on the OTC PINK under the new Qrons Inc. name and ticker symbol "QRON"  began at market open on August 10, 2017.

With the name change complete the Company is also arranging for application to make its shares DTC eligible.
 
The Company's new website under development will become www.qrons.com.
 
About the Company
Headquartered in Miami Florida, Qrons Inc. ("The Company") is a start-up preclinical stage biotechnology company engaged in developing solutions to combat neuro-degenerative diseases and neuronal injuries. The Company is working to develop a novel stem cell system to repair and regenerate neuronal damage. The system incorporates what the Company believes to be unique stem cell treatments, cell modifications and a novel delivery system. The Company's preliminary focus is on traumatic brain injury (TBI), although it believes such solutions may be effective in dealing with Parkinson's disease, Huntington's and Alzheimer's disease. The Company entered into a license and research funding agreement ("License Agreement") with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University of Samaria, based in Ariel, Israel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future drug development plans, other statements regarding future research and product development plans, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

####
Qrons Inc.
777 Brickell Ave, Suite 500   |  Miami, FL 33131  |  786.620.2140  |  info@qrons.com